REGENXBIO to Participate in the Piper Jaffray Geno
Post# of 301275
ROCKVILLE, Md., July 06, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq: RGNX ), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it will participate in the Piper Jaffray GenomeRx Symposium on Tuesday, July 11, 2017 at the Lotte New York Palace Hotel. REGENXBIO senior management will participate in the following gene therapy panels:
- Next Gen Advancements: Delivery, Promoters, Vectors and More, 9:30-10:05 a.m. ET
- Tackling Manufacturing, 11:20-11:55 a.m. ET
- The Eye, 12:40-1:15 p.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV ® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 617-340-6072 heather@argotpartners.com Media Adam Pawluk, 202-591-4063 apawluk@jpa.com
(0)
(0)